Wpływ cukrzycy na funkcję i rozwój chorób nerek

• Authors: Jaroszyński Andrzej , Jaroszyńska Anna
• Languages of publication: PL

Keywords

PL

cukrzycowa choroba nerek; przewlekła choroba nerek; dyslipidemia, albuminuria; nadciśnienie tętnicze

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2013
• Issue: 2
• Pages: 224-226

Contributors

author

Jaroszyński Andrzej

author

Jaroszyńska Anna

References

• Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabet Res Clin Pract 2010;87: 4.
• KDO QI Clinical Practice Guideline for Diabetes and CKD : 2012 Update. Am J Kidney Dis 2012; 60: 850–886.
• Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319–330.
• Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci 2013; 124: 139–152.
• Drong A, Lindgren C, McCarthy M. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012; 92: 707–715.
• Malecki M. Genetics of type 2 diabetes mellitus. Diabet Res Clin Pract 2005; 68: S10–S21.
• Hattersley A. Molecular genetics goes to the diabetes clinic. Clin Med 2005; 5: 476–481.
• Calcutt N, Cooper M, Kern T, et al. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009; 8: 417–423.
• Parving H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney. 7th ed. Philadelphia: Saunders; 2004:1777–1818
• Standards of medical care in diabetes. Diabet Care 2012; 35(Suppl. 1): 11–63.
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy.The Epidemiology of Diabetes Interventions and Complications (EDI C) Study. JAMA 2003; 290: 2159–2167.
• Wang P, Lau J, Chalmers T. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.Lancet 1993; 341: 1306–1309.
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med 2008; 358: 2560–2572.
• Matej-Butrym A, Butrym M, Jaroszynski A. Analysis of the causes of non-adherence to medical recommendations by patients with type 2 diabetes. Fam Med Prim Care Rev 2011; 13: 449–451.
• Heerspink H, Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011; 8: 392–402.
• ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.
• KDI GO Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Inter 2012; Suppl.2: 340–414.
• Upadhyay A, Earley A, Lamont J, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 251–262.
• Palmer S, Craig J, Navaneethan S, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263–275.
• Jenkins M, Goldsmith D. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?Curr Opin Cardiol 2012; 27: 429–440.